Jun 14, 2020
Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program
Jun 14, 2020
Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program
Jun 11, 2020
Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout
Apr 22, 2020
Invitation - Presentation of Sobi's Q1 2020 Results
Apr 22, 2020
Sobi(TM) Affiliate Florio GmbH, Launches a New Digital Platform Aiming to Improve the Lives of People with Haemophilia
Apr 20, 2020
Sobi Offers Advance Voting at the 2020 Annual General Meeting
Apr 17, 2020
New Data Shows Varied State of Haemophilia Treatment Around the World: Sobi
Apr 13, 2020
Sobi Sees Strong Revenue and EBITA Growth in the First Quarter 2020
Apr 07, 2020
Sobi(TM) Publishes 2019 Annual and Sustainability Report
Feb 28, 2020
New Research Uncovers the Toll Rare Diseases Take on Relationships
Feb 13, 2020
Sobi Publishes Report for the Fourth Quarter and Full-year 2019
Feb 04, 2020
Invitation - Presentation of Sobi's Q4/FY 2019 Results
Dec 21, 2019
FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia
Dec 09, 2019
Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates
Dec 09, 2019
Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
Dec 05, 2019
Data to be Highlighted at the American Society of Hematology 2019 Annual Meeting
Nov 10, 2019
Sobi Successfully Completes Tender Offer for All Outstanding Shares of Dova Pharmaceuticals
Oct 31, 2019
Sobi Publishes Report for Third Quarter 2019
Oct 23, 2019
Invitation - Presentation of Sobi's Q3 2019 Results
Aug 22, 2019
Sobi has Entered Into Agreement to Sell Priority Review Voucher